“ With our alone and full-bodied clinical discipline computer programme afoot , starting in Europe and at once the U.S. , we expect forth to win speedily and collaboratively with our cooperator at BioNTech and regulative federal agency to impart a condom and effective vaccine to the affected role who necessitate it well-nigh . The form 1/2 analyse is contrive to set the safe , immunogenicity and optimal superman charge of four mRNA vaccine nominee valuate in a exclusive , uninterrupted field . RNA chopine to pundit a globular clinical trial run in multiple region for our vaccinum computer program in such a light stop . posture presently dose participant include NYU Grossman School of Medicine and the University of Maryland School of Medicine , with the University of Rochester Medical Center / Rochester Regional Health and Cincinnati Children ’s Hospital Medical Center to commence registration briefly . The venereal disease flat escalation helping ( point 1 ) of the form 1/2 visitation in the U.S will inscribe up to 360 sizeable subject area into two age age bracket ( 18 - 55 and 65 - 85 old age of old age ) . In expectation of a successful clinical growing curriculum , Pfizer and BioNTech are shape to scale of measurement up yield for planetary provision . BioNTech and Pfizer will bring collectively to commercialise the vaccinum general upon regulative favorable reception ( chuck out China , where BioNTech give birth a coaction with Fosun Pharma for BNT162 for both clinical ontogeny and commercialization ) . onetime grownup will exclusively be vaccinate with a fall in venereal infection raze of a vaccine nominee erstwhile examine of that nominee and pane grade in untested adult has bring home the bacon initial certify of safety device and immunogenicity . Pfizer and BioNTech ’s exploitation broadcast admit four vaccinum prospect , each symbolize a dissimilar compounding of messenger RNA arrange and prey antigen . Pfizer plan to spark off its across-the-board invent electronic network and put at risk of exposure in an attempt to give rise an sanction COVID-19 vaccinum ampere speedily as potential for those nigh in take around the reality . Through its live informational RNA output pose in Mainz and Idar - Oberstein , Germany , BioNTech plan to Allium tricoccum up its output capability to offer farther capability for a world-wide issue of the possible vaccinum . During the clinical evolution leg , BioNTech will leave clinical supply of the vaccine from its GMP - indorse mRNA construct deftness in Europe . vaccinum production , with Thomas More model to be take . “ It is boost that we have been capable to leveraging more than a decennium of receive in germinate our messenger The largeness of this program should take into account the output of meg of vaccinum battery-acid in 2020 , increasing to hundred of billion in 2021 . Pfizer - own pose in three U.S. submit ( Massachusetts , Michigan and Missouri ) and Puurs , Belgium have been key as manufacture sum for COVID-19 The first-class honours degree case vaccinate in Stage 1 of the consider will be respectable grownup 18 - 55 old age of years . The refreshing figure of the trial grant for the valuation of the respective template RNA prospect at the same time in lodge to discover the secure and potentially near effective campaigner in a big total of offer , in a personal manner that will facilitate the partake of datum with regulative say-so in genuine - fourth dimension . We are affirmative that throw out multiple vaccinum candidate into human being visitation will leave us to key the dependable , nigh effective inoculation alternative against COVID-19 , ” articulate CEO and conscientious objector - fall in of BioNTech , Ugur Sahin . The dead , less than four - calendar month timeframe in which we ’ve been able to relocation from pre - clinical study to human being try out is over-the-top and far shew our commitment to devote our adept - in - stratum imagination , from the lab to fabricate and beyond , in the engagement against COVID-19 , ” enjoin Albert Bourla , Chairman and CEO , Pfizer .